US Patent

US9533053 — High concentration olopatadine ophthalmic composition

Formulation · Assigned to Alcon Research LLC · Expires 2032-05-19 · 6y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a high concentration ophthalmic composition containing olopatadine hydrochloride for providing relief from symptoms of ocular allergic conjunctivitis.

USPTO Abstract

The present invention is an ophthalmic composition containing a relatively high concentration of olopatadine. The composition is typically an ophthalmic aqueous solution containing relatively high concentrations of olopatadine solubilized within the solution. The composition is preferably capable of providing enhanced relief from symptoms of ocular allergic conjunctivitis, particularly late phase symptoms of ocular allergic conjunctivitis.

Drugs covered by this patent

Patent Metadata

Patent number
US9533053
Jurisdiction
US
Classification
Formulation
Expires
2032-05-19
Drug substance claim
No
Drug product claim
Yes
Assignee
Alcon Research LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.